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Preventing coronary heart disease
High baseline risk strategy and cost
effectiveness of guidelines
Editor—Manuel et al found, contrary to
Rose’s population health strategy, that a
high baseline risk strategy was the most
effective approach to coronary heart
disease prevention with a statin in Canada.1
This approach is consistent with new UK
guidelines.2 Using data from the nationally
representative Scottish health survey 1998
we estimate that 25% of 40-74 year olds
in Scotland would be eligible for primary
prevention of cardiovascular disease with a
statin when using this approach, with large
implications for prescribing budgets. The
annual cost in Scotland of treating all those
eligible with 40 mg generic simvastatin
would be £40m (€58m; $69.8m) and would
be substantially higher with branded statins.
In the Scottish health survey 2003, 51%
of men and 49% of women aged 55-64 years
had high blood pressure and the figure rose
to 77% for men and women aged 75 years
and older. Treating these patients with a thi-
azide diuretic would be an effective way of
reducing mortality3 and would be more cost
effective than statins.4 To date there has been
no trial evidence of an additional reduction
in all cause mortality with statins in patients
with thiazide treated hypertension, even in
the ASCOT trial.5
We believe that cost effectiveness of
guidelines should be considered before their
introduction with comparison to other,
potentially more cost effective, approaches
to the primary prevention of cardiovascular
disease. In addition to lifestyle measures
including weight management and smoking
cessation, these might include treatment
with low dose bendrofluazide if blood
pressure is found to be raised. In middle
aged and elderly patients this would bring
widespread population benefits, reminiscent
of Rose’s approach, and is likely to be
considerably more affordable and cost effec-
tive than using statins.
D Graham Mackenzie specialist registrar
Public Health Department, NHS Fife, Leven, Fife
KY8 5RR
gm@nhs.net
John Forbes reader in health economics
Sarah Wild senior lecturer in public health
School of Clinical Sciences and Community
Health, University of Edinburgh, Edinburgh
EH8 9AG
Philip Rutledge consultant in medicines management
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Patients are people, not cases
Editor—Everyone knows the importance of
seeing patients as people, not cases. But the
idea seems to have made a less successful
transfer in terms of risk reduction.
Lowering some factor by a small
percentage in everyone—regardless of level
of risk—requires seeing everyone as a
disease waiting to happen.1 2 It requires
people with no reason for concern to make
unnecessary adjustments to their lives in yet
another area. And it requires doctors to
provide more warnings about potential
problems, even as the time available for the
truly sick becomes more limited.
Joan McClusky medical writer
New York, NY 10003, USA
joanmcclusky@interlaceglobal.com
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Blood pressure lowering in
elderly patients with stroke
Editor—Mant et al say that the results of
PROGRESS are not applicable to the stroke
population in the community.1 One reason
cited is that patients in the community were
12 years older than those recruited to
PROGRESS. The authors explain the
dangers of aggressive blood pressure lower-
ing for people older than 80 and recom-
mend further urgent studies.
Guidance on blood pressure lowering in
people older than 80 is still lacking,2 but this is
no reason to deprive this group of appropri-
ate treatment. If, for example, a fit and active
81 year old woman has a minor stroke then it
seems appropriate to treat hypertension
aggressively. It may be unethical for this
patient to be recruited to a placebo arm of a
blood pressure lowering trial and be deprived
of treatment that may prevent a stroke.
It is thus simply not possible to perform
randomised controlled trials in all groups of
patients. Moreover, most studies actually ask
more questions than they answer. For many
cases, treatment is decided following discus-
sion between patient and doctor, with the
aid of the information provided by ran-
domised controlled trials.
Elliot Epstein consultant physician
elliotepstein832@hotmail.com
Anil Kumar specialist registrar, general and geriatric
medicine
Walsall Manor Hospital NHS Trust, Walsall, West
Midlands WS2 9PS
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Estimated glomerular filtration
rate needs UK consensus
Editor—Chronic kidney disease imposes
a substantial health burden, affecting 5%
of the population. The renal national
service framework recommends using the
estimated glomerular filtration rate as a
more sensitive marker for chronic kidney
disease than serum creatinine. The quality
and outcomes framework 2006-7 requires
the estimated rate to achieve six points for a
chronic kidney disease register and 21
points for measuring and treating blood
pressure in chronic kidney disease.1
In December 2005, 55 out of 58 UK
clinical biochemistry departments contacted
agreed to be interviewed about current and
proposed reporting of estimated glomerular
filtration rate and methods for estimated
glomerular filtration rate and creatinine.
Seventeen (31%) were providing some
degree of reporting (median 9 (range 1-24)
months). Three routinely reported the rate.
The remaining centres provided a limited
service to named consultants and general
practitioners.
The estimated glomerular filtration rate
was calculated by abbreviated (four variable)
modified diet in renal disease (MDRD)
equation (15 centres),2 the MDRD equation
(one centre),3 and the Cockcroft and Gault
equation (one centre).4 Serum creatinine
was measured by the kinetic Jaffe method in
all these laboratories by using different ana-
lytical platforms. One centre routinely
corrected the estimated glomerular filtra-
tion rate for ethnicity, nine provided no cor-
rection, two provided the correction if
ethnicity was stated, and five provided a
related comment.
Of 38 (69%) centres not providing
reporting, five had no plans to provide
the service, 24 were planning to start
within 12 months. These centres cited
information technology problems, con-
cerns over the workload of renal physicians,
and confusion concerning the calculation
of the rate as reasons for not introducing
reporting.
Routine reporting of estimated
glomerular filtration rate will become a
necessity, but the current provision will be
unable to support the quality and outcomes
framework for chronic kidney disease. Rec-
ommendations are urgently required to
standardise the approach to calculate
estimated glomerular filtration rate. We
believe that the Renal Association’s guid-
ance of using the abbreviated formula for
modified diet in renal disease should be
adopted.5 In the longer term, the measure-
ment of serum creatinine should be
standardised.
Annice Mukherjee specialist registrar in diabetes and
endocrinology
annicemukherjee@hotmail.com
Donal O’Donaghue co-chair renal advisory group for
renal NSF implementation
Aram Redenski consultant chemical pathologist
John New consultant physician and diabetologist
Salford Royal NHS Trust, Hope Hospital, Salford
M6 8HD
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Ipswich Hospital, Ipswich IP4 5PD
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Grieving the death of a child
Clinicians should ensure that lethal drugs
are handed back
Editor—Davies’s case reports of completed
suicide in recently bereaved parents are a
timely reminder of one of the few areas in
suicide prevention (access to lethality) where
clinicians can intervene to save lives.1
Within the anger of acute grief—case 1
describes “holding on” to the decreased per-
son beyond the usual grief experience1—the
child’s drugs can acquire a symbolic value.
The same applies to bereaved spouses who
may also come to see their late partner’s tab-
lets as hope that betrayed them.Gunnell and
Lewis provide a useful conceptual frame-
work in which to consider a person’s risk of
suicide2: a combination of predisposing plus
facilitating factors minus protective factors
such as social role, parenthood, help seeking
behaviours during crisis, and religious belief.
In the context of the sudden loss of many
protective factors, where most people’s cop-
ing skills would be overwhelmed by the loss
of a child, clinicians must identify access to
lethal overdose.
To ask grieving parents to “hand over
the medications” in the immediate after-
math of a death may seem unthinkable, but
preparation for this should be part of the
anticipatory grieving process.3 One solution
would be for carers to sign for controlled
drugs when home care is being arranged:
“These drugs are for the treatment of X and
must be returned to (named key worker) if X
leaves this address.” For other lethal drugs—
for example, insulin and cardiac drugs—
written consent from carers formalises their
safe return in the event of death or other
change in circumstances. As Davies points
out, relatives with high suicidal intent are
likely to deny this, making psychiatric assess-
ment unreliable during the immediate after-
math of a death. There are lessons here for
all hospital and community practitioners.
Peter Byrne liaison psychiatrist
Oldchurch Hospital, Romford RM7 0BE
p.byrne@ucl.ac.uk
Competing interests: None declared.
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Supporting health professionals who care
for grieving patients may benefit all
Editor—Davies outlined two cases of pallia-
tive care in the community for children
where mothers committed suicide after the
death of their children by using the remain-
ing opioid drugs.1 Supporting healthcare
professionals who work in palliative care,
and particularly in such circumstances,
could be as helpful for them as it may be for
their patients. Published work has recog-
nised that patients’ suicide has an impact on
psychiatrists.2 3 The qualitative study in
which I am currently participating (which
includes senior house officers (SHOs) in
psychiatry) has identified the traumatic
effect of suicide risk assessment on the
SHOs when the patient subsequently
attempted or committed suicide. The emo-
tional effects of such experiences have a last-
ing influence on the SHOs’ practice by
denting their professional confidence. The
feedback from the focus group interviews
that I have conducted so far includes
comments on the helpful aspects of sharing
such experiences and the feelings of guilt
and being blamed.
In the accompanying editorial, Raphael
addressed the complex issue of supporting
parents whose child is dying from a terminal
illness and the complexities of grief in such
circumstances.4 Despite recognising the
invaluable role of such support she seems to
be unconvinced by the evidence for provid-
ing bereavement support for families and
calls for “controlled trials” that would inform
the practice. The medical profession should
not need controlled trials to justify such
care. Anyone who is working with grieving
people will benefit from education and
training and from more informal ongoing
support in their work place. All this will
inform professionals about the complex
psychological reaction to loss, facilitate
empathy, improve the therapeutic relation-
ship, and ultimately be helpful to the
patients. Sharing such experiences in peer
reviewed journals, as Davies has done, is for
the benefit of all who work in health care.
Svetlin V Vrabtchev specialist registrar in
psychotherapy
Cedar House, Blackberry Hill Hospital, Bristol
BS16 2EG
svetlin.vrabtchev@awp.nhs.uk
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needles should be con-
sidered for gluteal injec-
tions in an increasingly
obese population.1
What is a longer nee-
dle? In the fifth edition of
the Royal Marsden Hospi-
tal Manual of Clinical
Nursing Procedures the
authors suggest the following needle
lengths, based on patient weight, for gluteal
intramuscular injections2:
31.5-40.00 kg: 2.5 cm needle
40.5-90.00 kg: 5-7.5 cm needle
> 90 kg: 10-15 cm needle.
They cite Lenz.3
Brian J Anthony lecturer
Middlesex University, Archway Campus, London
N19 5LW
b.anthony@mdx.ac.uk
Competing interests: None declared.
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Editor—We agree with Nisbet that standard
available needles may be inappropriate for
gluteal intramuscular injections, especially
when the incidence of obesity is increasing.1
However, his paper seems to exaggerate the
problem.
Firstly, there are other preferred sites for
intramuscular injections—for example, the
mid-deltoid, rectus femoris, and vastus
lateralis.2 Simpler clinical variables such as
the weight of the patient, muscle mass of the
injection site, and the amount of subcutane-
ous fat should be assessed for choosing the
correct needle length.3
In this study the sole criterion for the
assessment of subcutaneous fat at gluteal
region was the need to undergo the
computed tomography scans of the pelvis
without mentioning the indication for which
this was performed. Without knowing the
underlying indication it is hard to estimate
how many of these patients would have
required gluteal intramuscular injections.
Secondly, antiemetics and analgesics are
the common drugs given intramuscularly.
However, the gluteal region is not the most
practical intramuscular injection site in those
aged 25-65. These patients do not lie still in
bed. They either sit, stand, walk around, or
prefer to be injected in other sites.
Thirdly, the gluteal region is the more
often used site for intramuscular injections
in children, who are held by their parents,
and this age group was excluded from the
study.
Fourthly, non-ambulant and elderly
patients often have atrophy of the gluteal
muscles, and they represent the age group
of the patients who receive intramuscular
injections in the gluteal region
most often. This age group was
excluded from the study. Sur-
prisingly, age was not correlated
with dorsogluteal depth, for rea-
sons not mentioned in this
study.
Although the study tries to
address an important issue, it
does not show the true picture.
Saurabh Rai vascular research fellow
University Hospital Birmingham NHS Trust, Selly
Oak Hospital, Birmingham B29 6JD
saurabh_rai@hotmail.com
Nidhi Nandan senior house officer
Royal Shrewsbury Hospital, Shrewsbury SY3 8XQ
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Time to make paracetamol
with methionine available
Editor—What happened to the provision
of “safe” paracetamol that had been
campaigned for—that containing a judicious
amount of methionine, which reduced the
potential for overdose?
It was released for public purchase some
years ago, being designed to save lives, such
as those mentioned in Tanne’s article,1 but it
seems to have disappeared from the few
pharmacies’ shelves that stocked it seem-
ingly reluctantly. I say reluctantly because I
and several others made an effort to check
its availability for public purchase and were
astounded that most pharmacists when
asked for it either kept it “under the counter”
or “had to chase it up and would take a cou-
ple of days to obtain it”—and in almost every
case the purchaser was asked why he or she
would wish to purchase it when there was
some perfectly safe paracetamol without
methionine for sale already.
If “safe” paracetomol is available, and so
many people are dying of paracetamol
poisoning who could be saved through the
widespread sale of “safe” paracetamol,1 why
does the government’s health department
fail to ensure its widespread availability?
John P Heptonstall director
Morley Acupuncture Clinic, Leeds LS27 8EG
john@mac-tcm.demon.co.uk
Competing interests: None declared.
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Googling your treatment for
analgesia in labour
Editor—Giustini described how Google has
become the most powerful influence in
searching the internet.1 In a recent observa-
tional study on the labour ward at University
College Hospital, London, we found that
33% of pregnant women used the internet
as a source of information about labour pain
relief. This is a change from the results of a
previous study conducted five years ago in
Liverpool, in which the internet had been
used by less than 3% of pregnant women.2
We wondered what expectant mothers
would find on “Googling your treatment.”1
When searching for health information,
patients are known to look only at the first
few links after their search, and very few of
them later remember from which websites
they retrieved information or by whom the
sites were created.3
We feared that the one third of pregnant
women using the internet were accessing
information that was inaccurate and poten-
tially misleading their labour analgesia
choices. We performed a search at the main
Google UK site (not Google Scholar), using
“labour pain relief” as our criterion. The
search provided “about 3 300 000 results,” of
which we examined the top 10.
Six were written by or had direct contri-
bution from a doctor, two were articles in
peer reviewed journals, one was by a
midwife, and one was a commercial website
selling TENS machines. All of the non-
commercial websites were informative and
of high quality, providing balanced informa-
tion. We considered the information to be
anaesthetist friendly, and we were reassured
by our investigation.
In our internet savvy society, we suggest
that healthcare providers google their
particular topic to discover what kind of
information their patients are finding. A
cautionary note: as search engines continu-
ously update the pages to which they link
and their ranking, we advise regularly
repeating the search to keep up with the
dynamic flux of the internet.
James Holding research fellow
james.holding@uclh.nhs.uk
Michael V Holmes foundation year 1 trainee in
anaesthesia
Centre for Anaesthesia, University College
Hospital, London NW1 2BU
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Neonatal lupus erythematosus
is not always benign
Editor—The clinical case described by
Dennes and Nelson-Piercy in Minerva (with
photograph) described a baby with neonatal
cutaneous lupus.1
This is a benign and self limiting
condition when it is present in isolation, but it
should be emphasised that patients with neo-
natal lupus erythematosus have a substantial
risk of congenital heart block, a potentially
fatal complication. Neonatal lupus erythema-
tosus accounts for 80% of all cases of
congenital heart block.2 About half of the
reported cases of neonatal lupus erythemato-
sus have skin disease and half have congenital
heart block, with 10% having both.2 Congeni-
tal heart block is permanent and requires a
pacemaker in many cases. It also results from
the passive transfer of maternal autoantibod-
ies, anti-RoSSA and anti-La/SSB as in the
cutaneous manifestations. Therefore, all
babies with neonatal cutaneous lupus should
be investigated for congenital heart block.3
Andrew G Affleck specialist registrar in dermatology
Queen’s Medical Centre, Nottingham NG7 2UH
andyaffleck@doctors.org.uk
Competing interests: None declared.
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Independent sector treatment
centres: experience and spin
Editor—Independent sector treatment cen-
tres were recently praised by the Depart-
ment of Health.1 Ophthalmologists have
highlighted the problems experienced and
predicted for cataract centres.2–4 The govern-
ment argument that independent centres
provide value for money in elective surgery
is unconvincing because it considers “spot
purchasing” costs of “waiting list initiatives”
rather than the costs of planned NHS care.1
Procurement may drain the NHS of funds
that might otherwise be invested in compre-
hensive care in NHS hospitals.
Clinical quality in some ophthalmology
schemes has also been a concern.2 3 Further-
more, cataract waiting times had come down
before the mobile cataract independent sec-
tor treatment centres became operational.5
“Putting patients in charge of where they
are treated means that all providers have to
compete and this competition helps drive a
patient-centred service.”1 But offering unco-
ordinated choice at fixed tariffs may make
service planning and the financial viability
of NHS providers difficult. Unlimited choice
must be expensive. Experience suggests
most patients want quick access to good
local facilities. Cooperation—for example in
clinical networks—rather than competition
is thought to drive improved clinical quality.
Quality may become a hostage to market
forces when the bottom line is profit.
To date, no training in ophthalmology
has been provided in independent sector
treatment centres. No innovation has
emerged from those for cataracts—rather,
overseas teams have had to improve their
standards to reach NHS ophthalmology
standards.2 3 The much trumpeted innova-
tion of mobility is of uncertain benefit to
patients who often have to travel further to
reach these mobile units than to receive
conventional care locally. High volume NHS
cataract surgery operating lists can, and
often do, achieve the same numbers of
patients treated per session as in the mobile
units. However, NHS units also provide
holistic and comprehensive ophthalmology
care to all comers, and clinical training.
Reform and “self improvement” of NHS
services is also urged.1 However, most of the
process redesign now claimed existed in
initiatives such as the “Action on Cataract“
schemes.2 5 These self improvements are testi-
mony to both the innovative skills of NHS
ophthalmologists and the close collaboration
between hospital and primary care. These
professional leadership qualities may be lost
in the fragmentation of the current procure-
ment of the independent sector centres.
Simon P Kelly consultant ophthalmologist
Bolton Hospitals NHS Trust, Bolton BL4 OJR
spkelly@ntlworld.com
Competing interests: None declared.
1 Department of Health. Independent sector treatment cen-
tres. A report from Ken Anderson, Commercial Director.
London: Department of Health, 2006. www.dh.gov.uk/
assetRoot/04/12/91/08/04129108.pdf (accessed 10 Mar
2006.)
2 Royal College of Ophthalmologists. Response to the
Health Select Committee. New inquiry—independent sec-
tor treatment centres. London: Royal College of Ophthal-
mologists, 2006. www.rcophth.ac.uk/docs/college/
RCOphthResponsetoSelectCommitteeInquiryonISTCs.pdf
(accessed 10 Mar 2006.)
3 Kelly SP. Cataract care is mobile; is direction correct? Br J
Ophthalmol 2006;90:7-9.
4 Ferris JD. Independent sector treatment centres (ISTCs):
early experience from an ophthalmology perspective. Eye
2005;19:1090-8.
5 Kelly SP. Recurring policy errors: blind spots over
cataracts. Lancet 2005;366:1691.
Untreated controls are wrong
when proved treatment exists
Editor—Mudur in his news article reports
that Johnson & Johnson had added that “the
placebo controlled design was required to
satisfy the requirements of regulatory
authorities to allow their evaluation of the
risk/benefit of the drug” in compliance with
good clinical practice and the Declaration of
Helsinki.1
Article 29 of the Declaration of Helsinki
statesthatthebenefits,risks,burdens,andeffec-
tiveness of a new method should be tested
against those of the best current prophylac-
tic, diagnostic, and therapeutic methods.
This does not exclude the use of placebo, or
no treatment, in studies where no proved
prophylactic, diagnostic, or therapeutic
method exists.
The World Medical Association later
added a footnote, saying that “a placebo con-
trolled trial may be ethically acceptable, even
if proved therapy is available . . . Where for
compelling and scientifically sound meth-
odological reasons itsuse isnecessary todeter-
mine the efficacy or safety of a prophylactic,
diagnostic or therapeutic method.”2
However, “the placebo controlled design
was required to satisfy the requirements of
regulatory authorities” is hardly a scientifi-
cally sound reason—it is a commercial one.
J Martin Bland professor of health statistics
University of York, York YO10 5DD
mb55@york.ac.uk
Competing interests: None declared.
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Wear your name badge well
Editor—Essex is right to point out the
importance of introducing oneself in all
clinical encounters.1 However, the position
of the name badge may be acceptable at hip
height, depending on where patients are
seen, and in which specialty.
Despite my own short stature, most of
my patients are around hip height, and so
wearing my ID badge there is much easier
for them. In hospital most ward rounds are
conducted with the team standing, and so
for patients lying or sitting in bed, badges at
hip height are probably more easily read. In
outpatient clinics most consultations occur
while seated, and so a badge at breast height
is more appropriate.
Wherever you wear your badge, the
most important introduction and identifica-
tion is with a clear voice.
Simon Fountain-Polley specialist registrar paediatrics
Birmingham Heartlands Hospital, Birmingham
B9 5SS
pollgysim@yahoo.com
Competing interests: None declared.
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